These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10802149)

  • 1. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy.
    Aoki S; Hasegawa G; Shigeta H; Obayashi H; Fujii M; Kimura F; Moriwaki A; Nakamura N; Ienaga K; Nakamura K; Kondo M
    Diabetes Res Clin Pract; 2000 May; 48(2):119-25. PubMed ID: 10802149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy.
    Yamaguchi M; Nakamura N; Nakano K; Kitagawa Y; Shigeta H; Hasegawa G; Ienaga K; Nakamura K; Nakazawa Y; Fukui I; Obayashi H; Kondo M
    Diabet Med; 1998 Jun; 15(6):458-62. PubMed ID: 9632118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidation of spectrin and deformability defects in diabetic erythrocytes.
    Schwartz RS; Madsen JW; Rybicki AC; Nagel RL
    Diabetes; 1991 Jun; 40(6):701-8. PubMed ID: 2040386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
    Turk N; Mornar A; Mrzljak V; Turk Z
    Diabetes Metab; 2004 Apr; 30(2):187-92. PubMed ID: 15223992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.
    Schalkwijk CG; Ligtvoet N; Twaalfhoven H; Jager A; Blaauwgeers HG; Schlingemann RO; Tarnow L; Parving HH; Stehouwer CD; van Hinsbergh VW
    Diabetes; 1999 Dec; 48(12):2446-53. PubMed ID: 10580435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus.
    Kanauchi M; Kawano T; Dohi K
    Diabetes Res Clin Pract; 2000 May; 48(2):113-8. PubMed ID: 10802148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of glycosylated serum protein in patients with diabetic nephropathy].
    Li PL; Yang R; Zhou Y; Chen H; Cai DH
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1093-4. PubMed ID: 21690078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonenzymatic protein glycosylation. I. Lowered erythrocyte membrane fluidity in juvenile diabetes.
    Watała C; Zawodniak M; Bryszewska M; Nowak S
    Ann Clin Res; 1985; 17(6):327-30. PubMed ID: 4096489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of RBC membrane and serum lipid composition in Trinidadian type II diabetics with and without nephropathy.
    Nayak BS; Beharry VY; Armoogam S; Nancoo M; Ramadhin K; Ramesar K; Ramnarine C; Singh A; Singh A; Nwachi KU; Teelucksing S; Mathura R; Roberts L
    Vasc Health Risk Manag; 2008; 4(4):893-9. PubMed ID: 19066007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycosylation end products in patients with diabetic nephropathy.
    Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H
    N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical detection of advanced glycosylation end products in vivo.
    Makita Z; Vlassara H; Cerami A; Bucala R
    J Biol Chem; 1992 Mar; 267(8):5133-8. PubMed ID: 1371995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo.
    Obayashi H; Nakano K; Shigeta H; Yamaguchi M; Yoshimori K; Fukui M; Fujii M; Kitagawa Y; Nakamura N; Nakamura K; Nakazawa Y; Ienaga K; Ohta M; Nishimura M; Fukui I; Kondo M
    Biochem Biophys Res Commun; 1996 Sep; 226(1):37-41. PubMed ID: 8806589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
    Aso Y; Inukai T; Tayama K; Takemura Y
    Acta Diabetol; 2000; 37(2):87-92. PubMed ID: 11194933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria.
    Song KH; Ko SH; Kim HW; Ahn YB; Lee JM; Son HS; Yoon KH; Cha BY; Lee KW; Son HY
    Diabetes Care; 2005 Jul; 28(7):1718-23. PubMed ID: 15983325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.
    Bosman DR; Winkler AS; Marsden JT; Macdougall IC; Watkins PJ
    Diabetes Care; 2001 Mar; 24(3):495-9. PubMed ID: 11289474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.